Abbott Labs(ABT, Financial) agreedDec. 27 to the conditions imposed by the U.S. Federal Trade Commission for the closing of the deal that will see Abbott purchase St. Jude Medical (STJ, Financial) for a total consideration of $25 billion.
After Abbott Labs agreement on the FTCs conditions, there arent any other obstacles to Abbott's plan to purchase St. Jude Medical. Thus, the white smoke is expected anytime soon.
The conditions were imposed by the FTC in respect of certain antitrust rules. In particular, the FTC required Abbott to sell off two cardiovascular devices.
Last October the two U.S. companies agreed to sell St. Jude Medical's Angio-Seal and Femoseal, vascular closure products, and Abbott's Vado Steerable Sheath, a heart catheter, to Terumo Corp.(TSE:4543) for a consideration of approximately $1.12 billion.
Once the Abbott Labs-St. Jude Medical deal is completed, the combined business will have a positive impact on both shareholders and heart patients because the new business entity will be a leader in the cardiovascular market. Thus, it will contribute more effectively to the improvement of heart patients life quality and to the health care costs reduction.
A positive reaction to the news from the stock market is expected in todays negotiations.
Abbott closed at $38.60 per share Dec. 27, up 18 cents, or 0.47%, from the previous trading day, with 6,633,668 shares traded on the New York Stock Exchange (NYSE) versus an average volume of 7.6 million over the last 10 trading days and an average volume of 8.6 million shares over the last three months.
The stock is more volatile than the stock market (beta = 1.48) and underperformed with 25.05% the Standard & Poor's 500 year to date.
Abbott Labs has a market capitalization of $56.83 billion and 1.47 billion shares outstanding. The percentage of shares held by insiders is 0.21% and by institutions is 70.50%.
The number of shares available for trading is 1.47 billion. The price-earnings (P/E) ratio (TTM) is 25.48, the EPS (TTM) is $1.51 per share, and the dividend yield is 2.76%.
The company has approximately $4.51 billion of cash on hand or $3.06 per share. The total debt (mrq) is $8.51 billion, and the book value per share (mrq) is $14.06.
As of today, analysts suggest buying shares of Abbott, and the average target price is $46.85 per share.
During the third quarter, First Eagle Investment (Trades, Portfolio), George Soros (Trades, Portfolio) and Richard Pzena (Trades, Portfolio) reduced their positions in Abbot Labs by 57.24%, 21.26% and 5.81% while Joel Greenblatt (Trades, Portfolio) sold out his position.
Abbott is a member of the S&P 500 Dividend Aristocrats Index.
St. Jude Medical closed at $80.15 per share Dec. 27, up 32 cents or plus 0.40%, with a volume of 3,178,204 shares traded on the NYSE versus an average volume of 2.24 million traded over the last 10 trading days and an average volume of 2.41 million shares over the last three months.
As of Wednesday, 19 analysts out of a total of 20 suggest holding shares of St. Jude Medical, and the average target price is $81.96 per share.
St. Jude Medical has a market capitalization of $22.9 billion and approximately 285.72 million shares outstanding, of which 278.38 million can be traded on the NYSE, 2.43% is held by insiders, and 86.30% is held by institutions.
The company had $403 million in cash on hand and securities that can be readily converted into cash, as of the most recent quarter. The total debt amounted to $5.77 billion.
Disclosure: I have no positions in any stock mentioned in this article.
Start afree seven-day trialof Premium Membership to GuruFocus.
- First Eagle Investment Undervalued Stocks
- First Eagle Investment Top Growth Companies
- First Eagle Investment High Yield stocks, and
- Stocks that First Eagle Investment keeps buying
- George Soros Undervalued Stocks
- George Soros Top Growth Companies
- George Soros High Yield stocks, and
- Stocks that George Soros keeps buying
- Richard Pzena Undervalued Stocks
- Richard Pzena Top Growth Companies
- Richard Pzena High Yield stocks, and
- Stocks that Richard Pzena keeps buying